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KEY POINTS  
Accidental hypothermia was the primary or secondary diagnosis in over 100,000 hospital 
admissions from 2005 to 2015 in the United Kingdom. In this study we sought to determine 
whether acetaminophen, a non-prescription drug used to manage mild pain and fever, reduced 
core temperature stability during a 2-hour passive cold or thermoneutral exposure.  
Acetaminophen had no effect on core temperature in thermoneutral conditions compared with a 
placebo, but reduced core temperature by up to 0.57°C after 2-hours cold exposure. The present 
results improve our knowledge about the side-effects of acetaminophen and provides important 
information of relevance for hypothermia pathology. 
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ABSTRACT  
Background: Acetaminophen is an over-the-counter drug used to treat pain and fever, but it has 
also been shown to reduce core temperature (Tc) in the absence of fever. However, this side-
effect is not well examined in humans, and it is unknown if the hypothermic response to 
acetaminophen is exacerbated with cold exposure. 
Objective: To address this question, we mapped the thermoregulatory responses to 
acetaminophen and placebo administration during exposure to acute cold (10°C) and thermal 
neutrality (25°C).  
Methods: Nine healthy Caucasian males (age: 20 to 24 years) participated in the experiment. In a 
double-blind, randomised, repeated measures design, participants were passively exposed to a 
thermo-neutral or cold environment for 120-minutes, with administration of 20 mg/kg lean body 
mass acetaminophen or a placebo 5-minutes prior to exposure. Tc, skin temperature (Tsk), heart 
rate, and thermal sensation were measured every 10-minutes, and mean arterial pressure was 
recorded every 30-minutes. Data were analysed using linear mixed effects models. Differences in 
thermal sensation were analysed using a cumulative link mixed model.  
Results: Acetaminophen had no effect on Tc in a thermo-neutral environment, but significantly 
reduced Tc during cold exposure, compared with a placebo. Tc was lower in the acetaminophen 
compared with the placebo condition at each 10-minute interval from 80 to 120-minutes into the 
trial (all p < 0.05). On average, Tc decreased by 0.42 ± 0.13°C from baseline after 120 minutes of 
cold exposure (range 0.16 to 0.57°C), whereas there was no change in the placebo group (0.01 ± 
0.1°C). Tsk, heart rate, thermal sensation, and mean arterial pressure were not different between 
conditions (p > 0.05).  
Conclusion: This preliminary trial suggests that acetaminophen-induced hypothermia is 
exacerbated during cold stress. Larger scale trials seem warranted to determine if acetaminophen 
administration is associated with an increased risk of accidental hypothermia, particularly in 
vulnerable populations such as frail elderly individuals.  
 
Key Words: acetaminophen, paracetamol, thermoregulation, cold exposure, thermogenesis, 
hypothermia 
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1.1 INTRODUCTION 
Accidental hypothermia is characterised by an unintended core temperature (Tc) reduction to 
35°C or lower. Such a fall in Tc can induce ventricular fibrillation and ultimately cardiac arrest if 
Tc declines to < 28ºC [1, 2]. In the United States, hypothermia was the cause or contributing 
cause of death in over 5500 cases between 2006 and 2010 [3], but this is likely underestimated 
since Tc needs to be measured at or near the time of death. Nonetheless, data from United 
Kingdom hospital episode statistics indicate that hypothermia was the primary or secondary 
diagnosis in over 100,000 hospital admissions from 2005 to 2015 [4]. Although death from 
hypothermia is rare, it remains a significant health risk in elderly and very young individuals, 
particularly during winter months and unaccustomed cold spells [1]. Interestingly, there is a 
growing body of evidence demonstrating that acetaminophen could reduce Tc stability during 
cold exposure (discussed below), placing users at an increased risk of accidental hypothermia.  
Acetaminophen is an over-the-counter drug marketed as paracetamol in Europe and Tylenol in 
the United States. It is best known for its ability to decrease pain perception and reduce Tc during 
a fever; each of these actions are in part mediated through an inhibition of cyclooxygenase 
(COX) enzyme activity [5]. However, there is evidence of a ‘hypothermic’ action of 
acetaminophen, which refers specifically to an acetaminophen-induced reduction in Tc 
independent of febrile status. In mice, high doses (150 to 300 mg/kg body mass) administered 
intravenously reduced Tc by 2 to 4°C [6–8]. In humans, there have been 246 reports in Vigibase© 
(the World Health Organisation international database of adverse drug reactions) specific to 
acetaminophen-induced  accidental hypothermia [9]. In addition, several case studies report 
profound hypothermia following therapeutic doses [10] and high doses of acetaminophen when 
ingested orally [11, 12]. Finally, oral acetaminophen administration (20 mg/kg lean body mass) 
reduced Tc in young adults by ~0.2°C (range, 0.10 to 0.39°C) during exposure to mild cold [13]. 
Although the Tc reductions were small, this hypothermic side-effect of acetaminophen occurred 
in all thirteen participants. Despite this data, additional criteria, such as the environmental 
temperature, are needed to accurately predict when acetaminophen poses the greatest risk for 
hypothermia development. Since the COX pathway could be involved in non-febrile 
thermogenesis [14, 15], inhibition of this enzyme by acetaminophen might cause Tc to fall during 
cold exposure, while exerting negligible effects on Tc while exposed to a warm environment.   
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If acetaminophen-induced hypothermia is a risk during cold exposure, this can have major 
implications for public health recommendations. Each year in the United States, ~6% of adults 
are prescribed acetaminophen at doses of more than 4 g/day [16], while it is also available over-
the-counter without prescription. Acetaminophen is recommended as the first line analgesic for 
the elderly because it has minimal drug interactions and is well tolerated when taken at 
recommended doses [17]. It is also recommended for use in neonatal intensive care units 
following minor procedures and circumcision [18, 19]. Each of these age groups have a high 
incidence of accidental hypothermia due to a decreased ability to produce heat and make 
perceptually driven behavioural changes [20, 21]. Due to its hypothermic effects, use of 
acetaminophen in these populations could decrease their Tc to the point in which they are 
clinically hypothermic. However, the question remains as to whether acetaminophen exerts its 
hypothermic effect by increasing heat loss, or decreasing heat production. If the COX pathway is 
required for full heat production, inhibition of its activity by acetaminophen would cause Tc to 
fall during cold exposure while exerting no hypothermic action during a thermo-neutral exposure 
(in which no heat production is required).     
The aim of this trial was to examine the thermoregulatory response to acetaminophen 
administration (20 mg/kg of lean body mass) during a 120-minute exposure to a thermo-neutral 
and cold environment in healthy adult humans. Due to a potential role of COX in non-febrile 
thermogenesis [14, 15], it was hypothesised that acetaminophen would reduce Tc in cold 
conditions, but have no effect on Tc in thermo-neutral conditions relative to a placebo.  
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1.2 METHODS 
1.2.1 Ethical Approval 
Experimental procedures were approved by the University Research Ethics committee (approval 
code 2014ISPAR011). All experimental procedures conformed to the standards set by the World 
Association Declaration of Helsinki ‘Ethical Principles for Research Involving Human Subjects’. 
1.2.2 Sample Size Calculation  
Power analyses were conducted with GPower software version 3.1 (Heinrich University, 
Düsseldorf, Germany) to determine the sample necessary to achieve two-tailed statistical 
significance (α = 0.05), with a power of 0.90 and a partial eta-squared (η2) of 0.42. Using Tc data 
from a previous experiment where acetaminophen was tested as a hypothermic agent [22], it was 
determined that nine participants were required to reach the statistical power. If acetaminophen 
exerts the hypothesised hypothermic response, a larger project within vulnerable populations 
may be warranted to determine if acetaminophen contributes to accidental hypothermia 
admissions.  
1.2.3 Participants  
Nine Caucasian males [age: 22 ± 1 years, height: 179 ± 5 cm, body mass: 80.7 ± 11.9 kg, body 
fat (20 ± 5%)] volunteered to take part in this study. Participants were provided with written 
information regarding the experimental procedures, with supporting oral explanations from the 
principal investigator. All participants subsequently provided written informed consent. The 
participants were non-smokers, non-febrile (resting Tc < 38°C), and free from musculoskeletal 
injury. 
1.2.4 Inclusion & Exclusion Criteria 
Prior to each laboratory visit, participants completed an alcohol use disorder identification test 
[AUDIT; [23]], a breathalyser test (AlcoSense, One, Berkshire, UK), and an acetaminophen risk 
assessment questionnaire. To avoid any risk of liver damage inflicted by acetaminophen, 
participants were not able to participate in the research if they scored above ten on the AUDIT 
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questionnaire or alcohol was present in their bloodstream (i.e. > 0% blood alcohol content). In 
addition, the acetaminophen dose was relative to lean body mass, as it is a closer indicator of 
liver volume than total body mass [24]. No participants presented with any pre-existing medical 
conditions that may have put them at an increased risk of acetaminophen toxicity. Due to 
potential thermoregulatory adaptations [25, 26], individuals were not permitted to take part in 
any experimental procedures if they were heat/cold acclimated or acclimatised. Thus, those who 
had travelled to a hot/cold climate or participated in a laboratory based heat/cold acclimation 
protocol less than three weeks before the experiment were not permitted to take part. All 
participants presented to the laboratory with a stable resting Tc of 36.5-37.5°C. 
1.2.5 Experimental Design  
A schematic of the experimental design is displayed in Figure 1. To determine if acetaminophen 
reduces Tc stability during cold stress compared to a placebo, the participants visited the 
laboratory on five occasions, each separated by at least seven days. On visit 1, participants 
arrived fasted (overnight) and their body fat was assessed via air displacement plethysmography 
(Bod Pod, 2000A, Birmingham, UK). The body fat reading from this test was used to determine 
the participant’s dose of acetaminophen received in the experimental trials. Visits 2-5 
(experimental trials) were randomised (SPSS Inc., Chicago, USA), double blinded (drug only), 
and followed a repeated measures design. On these visits, participants were exposed to either 
cold [10°C, 40% relative humidity (r.h)] or thermo-neutral (25°C, 40% r.h.) environmental 
temperatures for 120 minutes, having been administered acetaminophen (20 mg/kg of lean body 
mass) or a placebo (dextrose). Acetaminophen (Paracetamol, Aspar Pharmaceuticals, London, 
UK) was administered via the oral route. The placebo was matched in terms of appearance i.e. 
the same number of capsules were provided to the participants. The average dose of 
acetaminophen administered in the present work was 1,287 ± 173 mg (range, 1,082 to 1,486 mg). 
 
***please insert Figure 1 near here*** 
 
1.2.6 Experimental Protocol 
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All participants arrived at the laboratory at 10:00. Upon arrival, participants were instrumented 
for the measurement of Tc, skin temperature (Tsk), and heart rate (see “Instrumentation and 
Equations” for details). Thirty minutes after arrival participants consumed a standardised 
breakfast [cornflakes (50 g), milk (250 ml) and 1 litre of tap water] and ingested acetaminophen 
or a placebo one hour after the meal was consumed. Participants remained rested in an upright, 
seated position between meal consumption and acetaminophen or placebo ingestion to ensure 
resting physiological status was attained. Participants were wheeled into the environmental 
chamber immediately following drug administration, and remained in the seated position for the 
duration of the protocol. Clothing was shorts and calf length socks, representing a Clo value of 
~0.1. Resting measurements of Tc, Tsk, heart rate and thermal sensation were collected five 
minutes prior to acetaminophen and placebo ingestion, and subsequently every 10 minutes for 
120 minutes’ post-ingestion. Blood pressure was measured prior to chamber entry and every 30 
minutes (pre-ingestion, 30, 60, 90, 120 minutes post-ingestion) until the end of the trial. Data in 
Tables 1 and 2 provide the mean and range for each variable (Tc, Tsk, heart rate, and MAP) at 30-
minute intervals.  
1.2.7 Instrumentation and Equations 
Tc was measured via insertion of a rectal thermistor (Henleys Medical Supplies, 400H/4491H, 
Hertfordshire, UK) 10 cm beyond the anal sphincter. The thermistor was connected via cable to a 
portable data logger (Libra Medical, ET402, Birmingham, UK), in which Tc was continuously 
displayed throughout each experimental protocol. This was only visible to the researchers, not 
the participants. 
Copper based thermocouples (Grant, EUS-U-VS5-0, Dorset, UK) connected to a wireless data 
logger (Grant, Squirrel Series, Dorset, UK) recorded Tsk at four sites: calf, thigh, chest, and 
triceps [27]. Thermocouples were securely attached to the belly of each muscle by hypafix 
surgical adhesive tape (BSN medical, D-22771, Hamburg, Germany). The weighted Tsk of four 
sites was subsequently calculated using the equation below [27]: 
 
Mean Tsk = 0.3×(Tarm + Tchest) + 0.2×(Tcalf + Tthigh) 
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Thermal sensation was obtained using a 0 to 8 scale ranging from unbearably cold (0) to 
unbearably hot (8). Heart rate was measured during all tests using short-range telemetry (Polar, 
FS1, Warwick, UK), and was expressed as beats per minute (b/min). 
Blood pressure was measured using a portable blood pressure monitor (Omron M5-1, Omron, 
Milton Keynes, UK). Measurements were taken at baseline (pre), and every 30 minutes of the 
120-minute exposure period. Mean arterial pressure (MAP) was later calculated as [(2 × DBP) + 
SBP]/3 mmHg. 
1.2.8 Statistical Analysis  
All statistical analyses were performed using the ‘nlme’, ‘ordinal’, ‘ez’, ‘sjPlot’ and ‘stats’ 
packages in R (version 3.3.2). Normality assumptions were checked using quantile-quantile plots 
[28] and were plausible in all instances. Central tendency and dispersion are reported as means ± 
standard deviation (SD). The Akaike information criteria (AIC) was used to determine model fit 
[29]. The correlation structure with the lowest AIC was chosen based on this procedure. A linear 
mixed model with fixed (‘drug’, ‘time’) and random (‘subject i.d’) effects was fitted with an 
autoregressive correlation structure (to account for autocorrelation) to examine the effect of 
acetaminophen on Tc, Tsk, and heart rate in thermo-neutral and cold conditions [Time (13 levels): 
pre, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120 minutes × Drug (2 levels): placebo, 
acetaminophen]. The same model with different levels of time [Time (5 levels): pre, 30, 60, 90, 
120 minutes) × Drug (2 levels): placebo, acetaminophen] was fitted to determine the effect of 
acetaminophen on MAP in thermo-neutral and cold conditions. A cumulative link model was 
used to compare thermal sensation scores between placebo and acetaminophen in the thermo-
neutral and cold conditions. The two-tailed alpha level of significance testing was set as p ≤ 0.05. 
95% confidence intervals (CI) are presented to denote the imprecision of the point estimate.  
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1.3 RESULTS 
1.3.1 Thermo-neutral 
There was no main effect for drug or interaction effect (drug × time) for Tc, Tsk, heart rate, TSS, 
or MAP. A main effect for time was present in each of these variables apart from MAP, showing 
that Tc, Tsk, heart rate and TSS changed (p < 0.05) over time with no differences observed 
between acetaminophen and placebo. Descriptive (mean ± SD) data for each 30-minute interval 
is shown in Table 1.  
1.3.2 Cold 
The Tc response during cold exposure differed between the acetaminophen and placebo 
conditions. An interaction effect (F1,12 = 2.25, p = 0.01), main effect for drug (F1,2 = 2.25, p < 
0.01), and main effect for time (F1,12 = 8.33, p < 0.01) was found between placebo (37.06 ± 
0.20°C; 95% CI = 36.99 to 37.12°C) and acetaminophen (36.90 ± 0.32°C; 95% CI = 36.79 to 
37.01°C). Specifically, Tc was 0.18, 0.19, 0.22, 0.27, 0.29 and 0.35°C lower in the 
acetaminophen trial at time points 70 to 120 minutes compared with the placebo. The peak Tc 
reduction in the nine participants (120 minute compared with baseline) was 0.16 to 0.57°C 
(mean = 0.40 ± 0.15°C). Mean and individual Tc responses over the 120-minute exposure period 
are displayed in Figures 2 and 3 respectively.  
There were no main effects for drug or interaction effect between drug and time for Tsk, heart 
rate, TSS, or MAP. A main effect for time was present in each of these variables excluding 
MAP. All descriptive data for each30 minute interval is shown in Table 2. For Tc, Table 3 
displays the model’s fixed effects coefficients and random effect variances.    
***please insert Table 1 & 2 near here*** 
***please insert Figure 2 near here*** 
***please insert Figure 3 near here*** 
***please insert Table 3 near here*** 
  
11 
 
1.4 DISCUSSION  
It was hypothesised that acetaminophen would reduce Tc in cold conditions, but have no effect 
on Tc in thermo-neutral conditions relative to a placebo. The experimental hypothesis was 
accepted. The major finding of the present study was that, compared with a placebo, 
acetaminophen administration reduced Tc (0.16 to 0.57°C decrease after 120 minutes exposure) 
during an acute cold stress (10°C), while it appeared to have no effect on thermoregulation at a 
thermo-neutral ambient temperature (25°C). During cold exposure, acetaminophen caused Tc to 
fall by ~0.40°C compared with the baseline value at 120 minutes, while it did not decline in the 
placebo trial. The variability in the response may be due to between subject differences in the 
rate of acetaminophen absorption, but unfortunately this was not analysed in this trial. The 
hypothermic response to acetaminophen ingestion observed in the current study corroborates our 
prior work in humans, in which acetaminophen reduced Tc by ~0.19°C in humans exposed to 
mild cooling [13]. Furthermore, this is the first study to demonstrate that the ambient temperature 
can dictate the degree of hypothermia induced by acetaminophen. During cold exposure, this 
trial shows that healthy young adults could not defend their Tc following acetaminophen 
administration (Figure 2). Given that elderly individuals already struggle to defend their Tc 
without prior drug ingestion [20], it is reasonable to suspect that acetaminophen would cause Tc 
to decline at a faster rate, increasing the risk of accidental hypothermia.    
The notion that ambient and skin temperature dictates the magnitude of acetaminophen’s 
hypothermic action is in line with previous research. In a recent experiment, acetaminophen (20 
mg/kg) had no effect on sweat output and Tc during 1-hour exercise in hot conditions (34°C, 52% 
r.h.) at a fixed rate of heat production (8 W/kg) [30]. In that study, the mean skin temperature 
increased by 1°C during the trial (up to ~35°C), a condition in which no heat producing 
mechanisms will be active [31, 32]. Because the mean skin temperature during cold stress was 
~24°C at the end of the trial (Figure 2), cutaneous vasoconstriction and active thermogenesis 
were required for Tc to remain stable [33, 34]. The presence of thermogenesis and 
vasoconstriction indicates that acetaminophen may reduce Tc through inhibition of at least one of 
these mechanisms, but the precise mechanism needs to be confirmed in future work. Previous 
data demonstrated that acetaminophen reduced Tc by 0.10 to 0.39°C (mean ± SD, 0.19 ± 0.09°C) 
at rest when the mean skin temperature was ~27°C [13]. Similar reductions in skin temperature 
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induce shivering thermogenesis [33], which, if inhibited by acetaminophen, may explain the 
small reduction in Tc seen previously [13].  
Studies in mice have shown Tc fell by 0.40, 0.80, and 2°C following 1-hour acetaminophen 
infusion of 100, 200, and 300 mg/kg body mass respectively [14]. Thus, acetaminophen-induced 
hypothermia is not only dependent on ambient temperature, but also on the dose administered. It 
is important to note here that mice are often housed in environments of 18 to 20°C, which is 8 to 
10°C beneath their normal thermo-neutral zone [35]. These housing conditions are consistent in 
experiments concerning acetaminophen-induced hypothermia in rodents [6, 8, 14], such that 
these animals constantly produce heat to maintain their Tc. Inhibition of this heat production 
through acetaminophen may explain its hypothermic action, a notion that should be confirmed 
through the administration of high dose acetaminophen in mice housed within and below their 
thermo-neutral zone (i.e. 30°C and 20°C, respectively).  
It is possible that the acetaminophen-induced reduction in Tc observed in the present study was 
due to inhibition of cyclooxygenase (COX). There are two COX isoforms (COX-1 and -2), and 
their function is to convert arachidonic acid to prostaglandin (PG) H2 [36], which cell-specific 
isomerases and synthases then convert to prostanoids [(PGE2, PGF2, PGD2, PGI2, and 
thromboxane A2 (TXA2)]. The  strongest evidence that acetaminophen-induced hypothermia is 
mediated through COX inhibition was provided by Ayoub and colleagues [14], who 
demonstrated that acetaminophen reduced Tc by 4°C in wild-type mice, but by only 1.5°C in a 
COX-1-/- strain. In addition, they showed a strong relationship between brain PGE2 
concentrations and Tc, where the maximum reduction in Tc was met with a 96% reduction in 
brain PGE2. Data supporting a role for a COX-1 splice variant (COX-1b) in the hypothermic 
effect of acetaminophen is equivocal. While infusion of putative COX-1b inhibitors aminopyrene 
and antipyrene exert a similar hypothermic effect to acetaminophen [14, 37], genetic studies 
suggest that the human COX-1b gene produces a non-functional protein because it retains intron-
1 [38]. Even when this was corrected via site-directed mutagenesis, acetaminophen did not 
inhibit COX-1b activity [39]. Taken together, these studies suggest that COX-1 mediated PGE2 
production may be required for normal Tc maintenance in mammals housed in sub-neutral 
ambient temperatures, while COX-1b is unlikely to be involved. If this were true, similar 
hypothermic responses would be expected with non-selective COX inhibitors Ibuprofen and 
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Aspirin, or SC-560, a COX-1 specific inhibitor. Whether these drugs initiate a loss of Tc control 
during cold exposure has not yet been determined.  
Given acetaminophen reduced Tc stability in healthy adult males (Figure 2), its hypothermic 
effect is likely to be larger in populations already considered vulnerable in sub-neutral ambient 
temperatures (i.e. the very young and the elderly). Accidental hypothermia is a rising global 
health concern. In the USA, the Centre for Disease Control and Prevention report that 
hypothermia was the cause of nearly 17,000 deaths from 1999 to 2011 [40]. In the UK, hospital 
episode statistics show that there were over 108,000 admissions to NHS hospitals from 2005 to 
2014, where hypothermia was the primary or secondary cause [4]. This database also shows that 
the very young (0-4 years; 43,868 admissions) and the elderly (≥ 65 years; 48,477 admissions) 
make up 85% of the total admissions. This is concerning for two reasons. Firstly, acetaminophen 
is the most frequently administered analgesic among frail and pre-frail elderly individuals [41], 
with no age-related delay in drug absorption [42]. Secondly, acetaminophen is commonly used 
for neonatal pain management [43]. In the perioperative setting, Tc monitoring after 
acetaminophen administration in these vulnerable groups is recommended. A 2011 study showed 
that intravenous acetaminophen (~20 mg/kg) did not cause hypothermia in 93 neonates [44]. 
However, the ambient temperature was not reported (presumably 23-25°C), and only the skin 
temperature was measured. This is problematic since our work showed a clear reduction in Tc 
without a change in skin temperature between acetaminophen and placebo [13]. Moreover, 
neonates are exposed to cold stress when wet with amniotic fluid, during transportation, or 
during surgery. Based on our data, we propose that acetaminophen may increase the risk of 
neonatal hypothermia only when coupled with one of these cold stressors, and not in a thermo-
neutral environment.  
1.4.1 Limitations  
This study has limitations that should be considered in future work. Firstly, we did not measure 
metabolic heat production or cutaneous blood flow, key parameters that control Tc during cold 
stress. Although a reduction in Tc from resting value is the primary variable of interest from a 
medical standpoint, it is still unknown what aspect of the thermoregulatory system 
acetaminophen targets to exert this effect. Measuring metabolic heat production and changes in 
cutaneous blood flow in future studies of a similar design may help to elucidate the mechanism 
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that regulates acetaminophen’s hypothermic action. Secondly, no pharmacokinetic parameters 
are reported in this experiment. Disparity in the plasma concentration of acetaminophen 
throughout each trial may have explained the between subject variability in the hypothermic 
response elicited by acetaminophen i.e. a low plasma concentration may result in a reduced 
hypothermic response. We administered a dose relative to lean body mass to reduce the 
variability in acetaminophen absorption, and our previous experiment showed that a 20 mg/kg 
lean body mass dose was appropriate for therapeutic plasma concentrations to be reached within 
the 120-minute exposure period [13].  
1.4.2 Conclusions 
In conclusion, this preliminary trial demonstrated that acute acetaminophen ingestion (20 mg/kg 
lean body mass) reduced Tc maintenance during acute cold exposure in healthy young adults. We 
are the first to show that the hypothermic action of acetaminophen is strongly influenced by the 
ambient temperature in which it is administered. Future research should determine if this effect is 
amplified in new-borns and in elderly individuals, placing them at risk of accidental 
hypothermia. It should also be determined if hypothermic effects are limited to acetaminophen, 
or are present in COX inhibitors such as Ibuprofen and Aspirin (non-selective COX inhibitors), 
or COXIBs (COX-2 selective inhibitors). If all COX inhibitors induce hypothermia during cold 
exposure, the prescription of these medications to individuals vulnerable to hypothermia should 
be carefully considered during cold spells and in the perioperative period.  
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Figure Captions: 
Fig 1. A flowchart of the study design. APAP = Acetaminophen. Visits 2-5 completed in a 
randomised order for each participant. Visits separated by 1-week and drug administration 
double blinded. 
Fig 2. Mean and SD of the Tc (A, C) and Tsk (B, D) response during the 120-minute exposure to 
25°C (left panel i.e. A, B) and 10°C (right panel i.e. C, D). The triangles and squares represent 
the placebo and acetaminophen trials, respectively. ∗ Main effect for condition. # Main effect for 
time. † Overall interaction effect. ‘a’ Interaction effect at a specific time point. Significance set at 
p < 0.05.  
Fig 3. Change in Tc during cold exposure in each participant following administration of a 
placebo (A) or acetaminophen (B). 
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Table 1. Descriptive data for each of the five response variables in the thermo-neutral condition (25°C). Descriptive data are the mean 
values (± standard deviation) during the 120-minute exposure period. The range is provided in parentheses. 
 Time-point (minutes) 
  Pre 30 60 90 120 
Tc (°C) 
Placebo 37.00 ± 0.13 (36.80 - 37.15) 
36.93 ± 0.15 
(36.72 - 37.13) 
36.95 ± 0.15 
(36.73 - 37.15) 
36.94 ± 0.14 
(36.75 - 37.15) 
36.94 ± 0.16 
(36.74 - 37.21) 
Acetaminophen 37.04 ± 0.20 (36.78 - 37.25) 
36.95 ± 0.22 
(36.78 - 37.14) 
36.93 ± 0.21 
(36.77 - 37.05) 
36.91 ± 0.23 
(36.68 - 37.10) 
36.89 ± 0.19 
(36.62 - 37.10) 
       
Tsk (°C) 
Placebo 30.6 ± 0.9 (28.7 - 31.8) 
30.9 ± 0.7 
(29.9 - 31.9) 
30.8 ± 0.7 
(29.8 - 31.7) 
30.7 ± 0.7 
(29.5 - 31.8) 
30.7 ± 0.7 
(29.3 - 31.7) 
Acetaminophen 30.3 ± 0.6 (29.0 - 31.1) 
30.8 ± 0.5 
(29.9 - 31.4) 
30.7 ± 0.4 
(29.9 - 31.2) 
30.7 ± 0.5 
(29.9 - 31.5) 
30.6 ± 0.6 
(29.6 - 31.6) 
       
HR (b/min) 
Placebo 65 ± 8 (53 - 79) 
59 ± 8 
(50 - 76) 
58 ± 10 
(46 - 79) 
58 ± 9 
(48 - 74) 
60 ± 10 
(49 - 86) 
Acetaminophen 68 ± 8 (53 - 81) 
62 ± 10 
(49 - 80) 
65 ± 10 
(50 - 84) 
59 ± 7 
(49 – 68) 
59 ± 10 
(42 - 71) 
       
TS (0 to 8 
scale) 
Placebo 4.0 ± 0.1 (4.0 - 4.5) 
4.1 ± 0.3 
(4.0 - 5.0) 
4.2 ± 0.4 
(4.0 - 5.0) 
4.3 ± 0.4 
(4.0 - 5.0) 
4.4 ± 0.6 
(4.0 - 5.5) 
Acetaminophen 4.0 ± 0.2 (3.5 - 4.5) 
4.2 ± 0.3 
(4.0 - 5.0) 
4.3 ± 0.4 
(4.0 - 5.0) 
4.4 ± 0.4 
(4.0 - 5.0) 
4.6 ± 0.5 
(4.0 - 5.0) 
       
MAP 
(mmHg) 
Placebo 91 ± 7 (83 - 103) 
91 ± 9 
(73 - 101) 
91 ± 10 
(81 - 113) 
92 ± 4 
(88 -  99) 
90 ± 6 
(82 - 99) 
Acetaminophen 88 ± 6 (80 - 97) 
91 ± 6 
(82 - 100) 
88 ± 9 
(78 - 111) 
88 ± 5 
(83 - 97) 
91 ± 6 
(85 - 104) 
Core temperature (Tc), Skin temperature (Tsk), Heart rate (HR), Thermal sensation (TS), Mean arterial pressure (MAP) 
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Table 2. Descriptive data for each of the five response variables in the cold condition (10°C). Descriptive data are the mean values (± 
standard deviation) during the 120-minute exposure period. The range is provided in parentheses. 
 Time-point (minutes) 
  Pre 30 60 90 120 
Tc (°C) 
Placebo 36.98 ± 0.20 (36.70 - 37.13) 
37.09 ± 0.19 
(36.79 - 37.38) 
37.03 ± 0.22 
(36.72 - 37.34) 
36.97 ± 0.23 
(36.71 - 37.29) 
36.96 ± 0.25 
(36.64 - 37.19) 
Acetaminophen 36.97 ± 0.21 (36.61 - 37.36) 
37.05 ± 0.26 
(36.59 - 37.49) 
36.94 ± 0.31 
(36.52 - 37.45) 
36.76 ± 0.30* 
(36.33 - 37.29) 
36.58 ± 0.23* 
(36.11 - 36.87) 
       
Tsk (°C) 
Placebo 30.5 ± 0.5 (29.6 - 31.3) 
25.8 ± 1.0 
(24.7 - 27.6) 
24.9 ± 1.0 
(23.8 - 26.9) 
24.4 ± 1.0 
(23.2 - 26.5) 
24.2 ± 1.0 
(22.8 - 26.6) 
Acetaminophen 30.7 ± 0.7 (29.6 - 31.8) 
26.1 ± 1.0 
(24.7 - 28.2) 
25.1 ± 1.0 
(23.7 - 26.6) 
24.5 ± 1.2 
(23.0 - 26.3) 
24.3 ± 1.3 
(22.4 - 26.5) 
       
HR 
(b/min) 
Placebo 68 ± 7 (54 - 79) 
62 ± 9 
(48 - 74) 
61 ± 4 
(55 - 67) 
57 ± 8 
(48 - 68) 
60 ± 9 
(51 - 75) 
Acetaminophen 66 ± 11 (50 - 79) 
59 ± 9 
(41 - 70) 
58 ± 10 
(39 - 73) 
54 ± 7 
(42 - 64) 
57 ± 9 
(41 - 70) 
       
TS (0 to 8 
scale) 
Placebo 4.1 ± 0.2 (4.0 - 4.5) 
2.8 ± 0.4 
(2.0 - 3.0) 
2.3 ± 0.5 
(1.5 - 3.0) 
1.9 ± 0.2 
(1.5 - 2.0) 
1.8 ± 0.4 
(1.0 - 2.0) 
Acetaminophen 3.9 ± 0.2 (3.5 - 4.0) 
2.3 ± 0.4 
(2.0 - 3.0) 
2.2 ± 0.4 
(1.5 - 3.0) 
1.8 ± 0.6 
(1.0 - 3.0) 
1.7 ± 0.5 
(1.0 - 2.5) 
       
MAP 
(mmHg) 
Placebo 92 ± 10 (78 - 104) 
97 ± 9 
(86 - 112) 
99 ± 8 
(90 - 110) 
97 ± 7 
(88 - 111) 
105 ± 8 
(92 - 117) 
Acetaminophen 93 ± 6 (78 - 102) 
94 ± 9 
(74 - 102) 
103 ± 7 
(91 - 111) 
96 ± 6 
(88 - 104) 
99 ± 6 
(77 - 104) 
Core temperature (Tc), Skin temperature (Tsk), Heart rate (HR), Thermal sensation (TS), Mean arterial pressure (MAP). * denotes 
significant difference between the APAP and placebo condition (p < 0.05). 
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Table 3. Beta coefficients (B), 95 % confidence intervals (CI), alpha values (p), and the Phi 
coefficient are reported for the fixed components (drug & time) during exposure to cold stress 
(10ºC). The standard deviation of the intercept and residual are reported for the random effect 
(subject ID). Bold values indicate a significant interaction effect between DRUG and TIME (p < 
0.05).  
    Core Temperature (ºC) 
    B CI p 
Fixed Parts  
Intercept   36.95 36.71 to 37.13 <.001 
Drug×Time Interaction     
DRUG:TIME10   0.03 -0.11 to 0.17 .694 
DRUG:TIME20   -0.03 -0.17 to 0.11 .672 
DRUG:TIME30   -0.06 -0.20 to 0.09 .442 
DRUG:TIME40   -0.10 -0.24 to 0.04 .179 
DRUG:TIME50   -0.12 -0.26 to 0.02 .109 
DRUG:TIME60   -0.13 -0.28 to 0.01 .076 
DRUG:TIME70   -0.18 -0.32 to -0.03 .021 
DRUG:TIME80   -0.21 -0.36 to -0.07 .006 
DRUG:TIME90   -0.24 -0.38 to -0.10 .002 
DRUG:TIME100   -0.29 -0.43 to -0.15 <.001 
DRUG:TIME110   -0.31 -0.45 to -0.17 <.001 
DRUG:TIME120   -0.36 -0.50 to -0.22 <.001 
Phi Coefficient  
0.938 
Random Parts (Subject ID) 
  Standard Deviation 
Intercept   0.13 
Residual   0.16 
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